Background: Controversy exists over how often and at what age mammography screening should be implemented. Given that evidence supports less frequent screening, the cost differences among advocated screening policies should be better understood.
T he frequency and appropriate age to start mammography screening for the detection of breast cancer have been debated in the United States for decades. Controversy intensified after the U.S. Preventive Services Task Force (USPSTF) recommended a change to biennial mammography on the basis that both annual and biennial screening reduce mortality rates, but biennial screening also decreases the negative effects (1) . However, in the United States, there has been resistance to reducing frequency or modifying the age range for mammography. The USPSTF guidelines conflict with professional organizations, such as the American Cancer Society, which recommend annual screening from age 40 years and continued regardless of a woman's age as long as she does not have serious, chronic health problems. Given the broad population that mammography serves, it is important to consider the economic effect of the conflicting guidelines.
In 2009, the USPSTF recommended biennial screening for women between the ages of 50 and 74 years, with consideration of screening women aged 40 to 49 years on a risk-benefit decision (2) . The USPSTF recommendations are based on a rigorous review of screening trials and work from the Cancer Intervention and Surveillance Modeling Network investigators that demonstrated that there is little net benefit in increasing the frequency of mammography (3) . The Cancer Intervention and Surveillance Modeling Network modeling is corroborated by evidence from the Breast Cancer Surveillance Consortium, showing that false-positive recall and biopsy rates are significantly lower in the setting of biennial screening but without a significant increase in detected later-stage cancer (4, 5) . The USPSTF recommendations on frequency are now in alignment with most European countries, where many of the defining mammography trials were conducted, with the exceptions of the United Kingdom and Finland, which screen every 3 years (6 -11) .
Screening in the United States is delivered locally or regionally and covered by myriad payer and health plan organizations. Thus, the total resources required or the cost-tradeoffs of different recommendations are currently unknown. This study was designed to inform the debate by estimating the lower bound of the aggregate annual cost of mammography screening in the U.S. population when current (2010) screening practices are compared with guideline-recommended screening strategies. Our findings should be valuable to women, clinicians, and health policymakers alike who are aware of the many conflicting guidelines.
METHODS

Study Design
To estimate the cost of mammography in the United States, we created a simulation model using mammography screening in 2010 as our base case. We then simulated 3 strategies (annual, biennial, and USPSTF) from the payer perspective. Analyses were done using R (R Foundation for Statistical Computing, Vienna, Austria). Table 1 shows the 4 screening strategies, 1 of which is an estimate of actual practice (18, 19) . The other 3 standardize on the population screened (85%) but differ on the age at which to start and stop and the frequency at which to screen. The biennial strategy represents the European approach, the annual strategy reflects the American Cancer Society (20) (among others) recommendations, and the USPSTF strategy (17) represents a risk-based strategy for screening those younger than 50 years and older than 75 years on the basis of their 2009 recommendations.
The final output of the model was the aggregate cost of mammography screening per year. The summation included the costs of mammography, computer-aided detection (CAD), and recalls and biopsies. A description of the modeling methods is available in the Supplement (available at www.annals.org).
Inputs and Variables
Model inputs were attained from several sources, including the Breast Cancer Surveillance Consortium (21), an observational data set designed to reflect mammography practice as it is done in the community and to reflect the distribution of women in the United States who have mammography, and they are listed in Table 1 (13, 15, 16, (22) (23) (24) . All input variables except costs were age-specific. The number of mammography screenings was calculated by determining the population of women at risk by using census data. To focus on screening as opposed to diagnostic or surveillance mammography, we limited the population of women at risk to those between the ages of 40 and 85 years and excluded the number of women diagnosed with breast cancer in the past 5 years, who should be receiving surveillance mammography.
We used data from the Behavioral Risk Factor Surveillance System 2010 Survey, a telephone health survey conducted by the Centers for Disease Control and Prevention, to determine the frequency and percentage of women receiving mammography. We corrected for survey bias by using the correction suggested by Rothman and colleagues (25). Although the survey does not distinguish between screening and diagnostic, we excluded women younger than 40 years and older than 85 years and those with recent history of breast cancer to best estimate screening as opposed to diagnostic mammography screenings (25). In our base-case model of actual practice, we included women who reported receiving mammography in the past 1 to 5 years and estimated the number who would have been screened in 1 given year; otherwise, the simulated strategies only simulated women receiving mammography every 1 or 2 years. The simulated strategies modeled a targeted participation of 85%, a screening participation achieved in the past for cervical cancer screening (26) . For the USPSTF strategy, we modeled 20% of women aged 40 to 50 years as high-risk. We then simulated biennial screening for this cohort on the basis of evidence that women aged 40 to 49 years with a 2-fold increased risk have similar harmsbenefit ratios from biennial screening as women aged 50 to 74 years with average risk (27). The USPSTF strategy also modeled screening women between the ages of 70 and 85 years who are healthy, defined as having fewer than 3 selfreported chronic conditions as reported by Medicare (28).
The percentage of recalled mammograms was obtained from the Breast Cancer Surveillance Consortium, using mammography screening performance data from 1 908 447 examinations for 749 597 women screened from 2001 to 2007. Following the Breast Imaging-Reporting and Data System manual (29), a recall was defined as an initial Breast Imaging-Reporting and Data System assessment of 0 (needs additional imaging evaluation), 4 (suspicious abnormality), 5 (highly suggestive of malignancy), or 3 (probably benign finding) if it was accompanied by a recommendation for immediate work-up. Separate estimates were computed for recall rates at first and subsequent mammography screenings (that is, prevalent and incident screenings) as well as stratified by frequency of screening, digital versus film mammography, and a woman's age.
Context
The total cost of alternative programs that screen for breast cancer is unknown.
Contribution
The actual cost of breast cancer screening in the United States in 2010 was $7.8 billion. The cost would have been $10.1 billion for screening every year, $2.6 billion for screening every 2 years, and $3.5 billion for screening according to recommendations from the U.S. Preventive Services Task Force.
Caution
These results depend on assumptions, not all of which are equally well-supported.
Implication
Dollars saved under less expensive programs could be used to screen women who are not being screened.
-The Editors
Original Research Aggregate Cost of Mammography Screening in the United States
The estimated costs of the modeled strategies include the cost of screening mammography and the subsequent recall costs. Costs for mammography and CAD were determined using 2010 national Medicare reimbursements rates (16) . Recall costs were calculated from the DMIST (Digital Mammographic Imaging Screening Trial) results of work-up costs, including additional imaging and biopsies from false-positive and true-positive examination results (24) . We adjusted DMIST recall costs proportional to the use of digital versus film mammography in 2010. We adjusted all cost data to 2010 U.S. dollars on the basis of inflation as estimated by the medical portion of the Consumer Price Index (30).
Sensitivity Analysis
We used Monte Carlo simulations to estimate the uncertainty of our total cost estimates and quantify the sensitivity of the output (total cost) to the model inputs (Supplement) (31) . In the sensitivity analysis, all terms in the formulas were assumed to be independent and follow ␤-distributions as detailed in Supplement.
Role of the Funding Source
This study was funded by the University of California and Safeway Foundation. The funding source had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. 
Cost computationsሻ
Number of women at risk Number of women Ϫ Number of women receiving surveillance mammography Number of digital mammography screenings
Number of women at risk ϫ Proportion of women screened ¶ ϫ Proportion of digital mammography screenings Number of film mammography screenings
Number of women at risk ϫ Proportion of women screened ¶ ϫ Proportion of film mammography screenings Number of CAD screenings
Number of women at risk ϫ Proportion of women screened ϫ Proportion of CAD screenings Number of digital recalls Proportion recalled after mammography ϫ Number of digital mammography screenings Number of film recalls Proportion recalled after mammography ϫ Number of film mammography screenings Total cost Number of digital mammography screenings ϫ Cost of digital mammography ϩ Number of film mammography screenings ϫ Cost of film mammography ϩ Number of CAD screenings ϫ Cost of CAD ϩ Number of digital recalls ϫ Cost of digital recall ϩ Number of film recalls ϫ Cost of film recall CAD ϭ computer-aided detection; USPSTF ϭ U.S. Preventative Services Task Force. * With calculated correction for self-reported data in the Behavioral Risk Factor Surveillance System (17) . † The population of women from the census (14) , excluding women with breast cancer in the past 5 y. ‡ Data provided by the Breast Cancer Surveillance Consortium. § Costs are in 2010 U.S. dollars. A probabilistic sensitivity analysis was done to assess the effect of each variable on the aggregate cost. The variables were assumed to follow ␤-distributions as detailed in the Supplement (available at www.annals.org). ¶ Proportion of women screened varied depending on screening strategy modeled. The base-case modeling actual screening practice averaged the proportion of women screened in 1 y that had been screened over every 1, 2, 3, 4, and 5 y. Annual strategies screened 85% of all women at risk in a given year. Biennial and USPSTF strategies screened 42.5% of women per year (85% of women at risk every 2 y).
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RESULTS
Our model simulated screening practices in 2010 and estimated the aggregate U.S. population cost of mammography per year. Three mammography screening strategies advocated by various professional societies with targeted participation rates were also simulated and yielded costs that ranged from $10.1 billion for the most to $2.6 billion for the least intensive screening strategies (Figure 1) .
The Aggregate Cost of Mammography Screening in the United States
We estimated the aggregate cost of mammography screening in the United States by simulating screening for women aged 40 to 85 years, which follow a mixture of screening strategies in actual practice. Given the disparate recommendations and the reality of screening in the United States, a woman who has had mammography in a given year may follow annual screening guidelines or biennial guidelines or be screened irregularly. We modeled participation rates from 61% of women between the ages of 40 and 45 years to 75% of women between the ages of 65 and 70 years (15) . Simulating this mix of actual mammography screening practices for women aged 40 to 85 years, we estimated the aggregate cost of mammography screening in 2010 to be in the range of $7.8 billion.
Estimated Cost of Proposed Screening Strategies With Targeted Participation
The results of the estimated costs of the annual, biennial, and USPSTF mammography screening strategies are summarized below and in Table 2 .
According to our model, annual screening of women between the ages of 40 and 84 years is estimated to cost $10.1 billion per year. This strategy follows the guidelines of many policymaking medical groups and would increase mammography screening costs by $2.3 billion per year from actual practice.
Biennial screening of 85% of women aged 50 to 70 years is estimated to cost $2.6 billion per year, the least expensive of the strategies. The biennial strategy is $7.7 billion less than annual screening of the 85% of the population aged 40 to 84 years and $5.4 billion less than what is estimated to be spent in actual practice.
The USPSTF strategy simulates biennially screening women aged 50 to 74 years and includes screening of highrisk women aged 40 to 49 years and women aged 75 to 85 years with fewer than 3 comorbid conditions. Screening women according to the USPSTF guidelines is estimated to cost $3.5 billion per year. With the same targeted participation rates of 85%, a USPSTF strategy is estimated to cost $6.7 billion less than an annual mammography strategy. The USPSTF strategy covering 85% of the population costs $4.4 billion less than actual practice.
Sensitivity Analysis
We used a sensitivity analysis to determine the inputs to which the model was most sensitive (or in other words, which inputs had the most effect on the cost outcomes of the model) (Figure 2) . Frequency of screening was the largest driver of cost and the input to which the model was most sensitive. Varying the frequency of screening from biennial to annual had a cost difference of more than $7 billion.
The next-largest drivers of costs for the model in decreasing order of effect were the variation of the percentage of women screened, percentage of film versus digital mammography, the cost of individual mammography screenings, number of recalls, and recall cost (Figure 2) . Each input was varied across a range of likely possibilities. Because digital mammography and CAD are becoming the standard, we estimated the cost of a complete shift to these methods; although only approximately $70 more per mammography screening, this would cost an additional $1.2 billion compared with actual practice (where digital and CAD are used for approximately 82% and 27% of all mammography, respectively). The effect of increased costs per mammography screening is less for strategies with lower screening frequency.
A sensitivity analysis was done for each screening strategy (Figure 2) . The major drivers of cost remained consistent for all 4 strategies; however, the cost of screening for each strategy, varying the range of inputs, differs greatly. 
USPSTF
Actual Annual
Each bar represents the total cost of mammography screening per year, demarcating the costs from screening mammography and the subsequent recalls and biopsies. USPSTF ϭ U.S. Preventive Services Task Force.
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The magnitude of change is billions of dollars for each strategy, but each varies around its estimated overall screening cost per year and there is little overlap in projected costs.
Given that Medicare reimbursements rates are at the lower bound of costs, we additionally estimated the effect on aggregate cost for each screening strategy per 10% increase in mammography, CAD, and recall costs. For each 10% increment greater than Medicare costs, the aggregate costs increase by $700 million for actual practice, $1 billion for annual screening, $270 million for biennial screening, and $350 million for the USPSTF strategy.
DISCUSSION
Our study shows that mammography screening in the United States, as currently implemented, is estimated to cost approximately $7.8 billion per year. A USPSTF strategy that screened 85% of U.S. women would save $4.4 billion dollars and screen 15% more women compared with current practice. If an annual strategy were implemented to screen 85% of the population, it would cost an estimated $10.1 billion per year, or $2.3 billion more than current practice. Finally, screening biennially and eliminating screening for women in their 40s or those who are older than 70 years would cost $2.6 billion, which is not much less than the broader USPSTF strategy.
In 2001, the aggregate cost of mammography was estimated to cost $3 to $5 billion for all U.S. women of screening age (32) . A study focused on the cost of breast cancer screening for the fee-for-service Medicare population used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to estimate screening cost per beneficiary billed during 2006 to 2007 and multiplied the total number of Medicare beneficiaries to estimate a cost greater than $1 billion annually for this subset of older female Medicare beneficiaries (33) . This result is consistent with our analysis considering the use of 10% to 20% digital mammography during that earlier period. They also noted that increases in the unit cost of mammography, from digital mammography and CAD, explained 65% of the difference in the regional variation of costs. The introduction of digital mammography confers many advantages, including ease of finding previous films; eliminating film processing; the opportunity to improve recall rates by reducing Breast Imaging-Reporting and Data System 0 mammograms, which need additional imaging evaluation; and instituting better biopsy thresholds. The effect of mammography cost changes, such as the increased use of digital, is much less when mammography frequency is lower. Our analysis identifies alternative strategies that will maintain screening performance but can lower the associated burdens by reducing additional recalls and biopsies using fewer resources.
Mammography frequency and age appropriateness affect the cumulative number of abnormal examinations that require supplemental imaging, clinical evaluation, and possible biopsy. Over the past decade, we have come to realize more of mammography's limitations (34, 35) . Studies have shown that annual mammography does not have a large benefit for cancer detection compared with biennial screening (3, 4, 27) . However, annual compared with biennial screening is associated with a greater likelihood of falsepositive recalls (61.3% vs. 41.6%) and biopsy results (7% vs. 4.8%) over 10 years (4). Such consequences affect women's well-being and quality of life (36, 37) . The costs per quality-adjusted life-years for annual compared with biennial mammography are more than $340 000 for all ages, well beyond the $75 000 to $100 000 per qualityadjusted life-year that is considered a cost-effective intervention (18) . The Cancer Intervention and Surveillance Modeling Network modeling group projected that women with a relative risk of 1.9 (range, 1.5 to 4.4) for breast cancer were the women likely to benefit from biennial screening in their 40s (27). To determine the appropriate age to start screening, experts recommend risk-based approaches for personalized screening, which is more in line with USPSTF guidelines (38) . The implementation of the Affordable Care Act is expected to increase mammography screenings by 500 000 per year as access improves (39, 40) . Disparities in mammography relate to access to high-quality facilities and use of breast imaging specialists to read mammograms (41, 42) . Mammography quality is improved when read by dedicated mammographers at high-quality facilities, which would also likely lower recalls, a large driver of screening costs (43) . Recall rates vary significantly nationally and internationally, and the average recall rates in the United States are 2 to 3 times those reported in Europe (44 -47) . Biennial screening policies that target age-appropriate women make high-quality mammography available to more women while reducing their travel and time burdens.
The Institute of Medicine report, "Best Care at Lower Cost," describes opportunities to reduce costs and improve the value of health care, including missed prevention opportunities ($55 billion) and inefficiently delivered services ($130 billion) (48) . Tailored screening policies address improved care at lower cost. As our analysis suggests, similar or higher-quality screening can be obtained at similar or lower costs, freeing resources for risk-assessment and prevention that are not currently part of screening. Learning to set better thresholds for recall and biopsy would also safely generate substantial savings and reduce burden on women (49, 50) .
Limitations of this analysis include mammography participation rates that used a correction to the Behavioral Risk Factor Surveillance System and used rates lower than the Centers for Disease Control and Prevention's estimates of 72% to 79% (40) . We used Medicare costs, which are at the lower end of reimbursement rates, and thus actual costs could be substantially higher. Recall costs were inflated to 2010 costs from 2005 data; however, current diagnostic work-ups may now be more expensive with greater use of imaging technology, such as magnetic resonance imaging. We did not evaluate time (direct nonmedical or indirect) costs. The additional cost of digital mammography compared with film was only modeled for the actual costs of the mammography and not associated ones. We did not model the overall costs of a missed diagnosis, although evidence suggests that biennial screening is not associated with a statistically significant increase in the diagnosis of late-stage cancer in women aged 50 to 74 years and that screening costs do not make a significant difference in the costs of initial cancer treatment (4, 5, 33) . We did not address the effect of possible overdiagnosis on costs (34, 50) . Mammography practices may have changed since 2010 to align actual practice with USPSTF guidelines; however, recent studies have shown that since the release of the guidelines, screening practices have not greatly changed Tornado diagrams depict sensitivity analyses done for the largest determinants of cost for each strategy. The x-axis shows the cost of mammography screening per year. The vertical line within each tornado diagram is the point estimate of cost for each strategy, and the horizontal bars represent the effect on cost the input ranges have in the sensitivity analyses. Frequency is the largest driver of cost as demonstrated by the wide range of cost between the least frequent strategy, biennial screening, versus the most frequent strategy, annual screening. The next largest drivers of cost, by decreasing level of effect, were the variation of the percentage of women screened, the cost of individual mammography screenings, percentage of film versus digital mammography, the number of recalls, and the recall cost. USPSTF ϭ U.S. Preventive Services Task Force.
Original Research Aggregate Cost of Mammography Screening in the United States (12) . Lastly, we excluded the cost of screening women younger than 40 years and older than 85 years to simplify guidelines and focus on screening; however, screening women outside of recommended policies is likely to have similar costs across strategies. The accumulation of assumptions is likely to make the projected costs an underestimate for each strategy. This analysis was not intended to provide a highly accurate point estimate but rather an approximate range and relative ranking of the costs for each strategy.
Although an individual mammography screening is not expensive, the aggregate national cost of screening millions of women is enormous. Costs of false-positive recalls and biopsies are also magnified and contribute to making mammography so resource-intensive. Better understanding of the limitations of mammography will enable using this screening tool more effectively. A screening policy following the USPSTF guidelines uses fewer resources, has fewer false-positive biopsy results and recalls compared with annual screening, and is being incorporated into quality guidelines (51) . Those who advocate annual screening should justify the increased costs of nearly $7 billion per year compared with biennial policies.
The billions saved from avoiding less-effective mammography screening could alternatively be used to improve women's health, including increasing participation in screening; routine assessment of breast cancer risk and referral for breast cancer prevention services if at high risk, especially for women younger than 50 years; genetic counseling for women with strong family history (12); alternative methods for screening women with dense breast tissue; and supporting a more programmatic or public health approach to screening (as in Europe) with double-reading, screening by invitation, and outcomes tracking. Resources can be better allocated to improve screening, with the emphasis on higher-quality mammography read by specialized mammographers (43) . More resources should go into improving the quality of the reads rather than simply a greater frequency. It is also clear that greater unit reimbursement costs have less effect on aggregate costs when the frequency is lower, such as with the USPSTF recommendations. Many publications have demonstrated that the most experienced readers, or systems of double-reading, improve sensitivity as well as specificity (51) . As our sensitivity analysis demonstrates, the frequency of screening-not the cost per screen-is the largest driver of cost. High-quality interpretation should be covered because it would improve screening performance and reduce recall costs. Current screening participation rates fall short of national goals (52) , and although the Affordable Care Act aims to improve access, using mammography effectively following guidelines, such as the USPSTF, will ensure that resources exist to expand screening participation.
In conclusion, mammography screening is resourceintensive at an estimated cost of $7.8 billion per year as currently practiced. Following mammography screening guidelines, such as those from the USPSTF, that optimize frequency on the basis of best available evidence will put us in a position to improve screening and save billions of dollars that can be invested in personalized risk-based screening and prevention strategies. Such a change in screening practice is likely to improve the quality of screening and is in line with our national goals of advancing health care delivery while improving cost-efficiency.
